Condition

Hereditary Breast and Ovarian Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting4

Common interventions21

Lead sponsors shown15

Clinical trials

19 shown

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and TestingNCT05130606 · 2021-06-01

RECRUITING

Familial Investigations of Childhood Cancer PredispositionNCT03050268 · 2017-04-06

RECRUITING

Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in SwitzerlandNCT03124212 · 2017-04-01

RECRUITING

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier RegistryNCT02302742 · 2011-03-22

RECRUITING

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer PredispositionNCT05721326 · 2023-05-01

COMPLETED

Scalable Communication Modalities for Returning Genetic Research ResultsNCT04407611 · 2023-03-06

COMPLETED

Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch SyndromeNCT04508764 · 2021-04-09

TERMINATED

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk DetectionNCT04668521 · 2020-05-04

TERMINATED

Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)NCT05409222 · 2020-03-12

UNKNOWN

Evaluation of the Adhesion to the GENEPY NetworkNCT03979612 · 2019-08-01

UNKNOWN

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.NCT03246841 · 2017-09-21

ACTIVE_NOT_RECRUITING

Genetic Risk: Whether, When, and How to Tell AdolescentsNCT03421327 · 2017-09-01

COMPLETED

Testing an Intelligent Tutoring System to Enhance Genetic Risk AssessmentNCT03511690 · 2017-07-01

COMPLETED

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian CancerNCT03075540 · 2016-05-24

COMPLETED

Identification and Referral of Women at Risk for Hereditary Breast/Ovarian CancerNCT02786147 · 2016-04-01

COMPLETED

Efficacy of Lifestyle Intervention in BRCA1/2 Mutation CarriersNCT02516540 · 2015-03-01

UNKNOWN

Cancer Genetics Hereditary Cancer Panel TestingNCT02324062 · 2014-06-12

COMPLETED

Feasibility of Lifestyle Intervention in BRCA1/2 Mutation CarriersNCT02087592 · 2014-02-01

COMPLETED

Radical Fimbriectomy for Young BRCA Mutation CarriersNCT01608074 · 2012-01-09

ACTIVE_NOT_RECRUITING

Common interventions

Leading sponsors

Georgetown University 3 Technical University of Munich 2 Abramson Cancer Center at Penn Medicine 1 Aspira Women's Health 1 Boston University 1 Centre Oscar Lambret 1 Emory University 1 Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 1 Institut Claudius Regaud 1 Johns Hopkins University 1 St. Jude Children's Research Hospital 1 UNICANCER 1 University of Basel 1 University of Kansas Medical Center 1 University of Southern California 1

Trial status mix

COMPLETED8

RECRUITING4

UNKNOWN3

ACTIVE_NOT_RECRUITING2

TERMINATED2

Phase mix

NA10

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.